Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

46.74
+0.60001.30%
Post-market: 46.810.0700+0.15%19:59 EDT
Volume:10.91M
Turnover:511.14M
Market Cap:206.73B
PE:11.68
High:47.17
Open:46.35
Low:46.34
Close:46.14
52wk High:64.16
52wk Low:35.12
Shares:4.42B
Float Shares:3.19B
Volume Ratio:0.82
T/O Rate:0.34%
Dividend:1.72
Dividend Rate:3.68%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:6.35
PE(LYR):12.91

Loading ...

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

TIPRANKS
·
Aug 01

Exchange Traded Funds Top 10 Percentage Losers

Dow Jones
·
Aug 01

Nasdaq Composite Index Rises 1% as Amazon Surges 15% After Results; Apple and Micron Fall as Memory Stocks Retreat

TradingKey
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

European Stocks Wipe Out Monthly Gains as Novo Nordisk and Universal Music Plunge

Deep News
·
Aug 01

Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled

TradingKey
·
Aug 01

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

MT Newswires Live
·
Aug 01

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 01

Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure

TradingKey
·
Jul 31

Novo Nordisk's Stock Slumps After Failed Trial - Adding to the Company's Woes

Dow Jones
·
Jul 31

Movement Alert|Novo-Nordisk A/S Falls 8.2% in Regular Trading, Heart Drug Ziltivekimab Fails Phase 3 ZEUS Trial Primary Endpoint

Market Focus
·
Jul 31

Novo Nordisk Heart Drug Trial Failure Triggers Pre-Market Plunge, Deepening Concerns Over Weight Loss Drug Reliance

Stock News
·
Jul 31

Sector Update: Healthcare

MT Newswires Live
·
Jul 31

Novo Nordisk Share Fall Seems Justified by Loss of Big Sales Opportunity

Dow Jones
·
Jul 31

Cardiac Drug Trial Failure Sinks Novo-Nordisk Stock Over 9%

Deep News
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell

MT Newswires Live
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events Risk in Phase 3 Trial

MT Newswires Live
·
Jul 31

Novo Nordisk’s Key Drug Trial Misses Primary Endpoint amid Shareholder Litigation Risks Over Weight-Loss Drugs

Market Focus
·
Jul 31

Here Comes the Next Wave of GLP-1s. They'll Treat a Lot More than Obesity.

Dow Jones
·
Jul 31

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 30